Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers

Tucci, Chiara Di; Schiavi, Michele Carlo; Faiano, Pierangelo; D’Oria, Ottavia; Prata, Giovanni; Sciuga, Valentina; Giannini, Andrea; Palaia, Innocenza; Muzii, Ludovico; Panici, Pierluigi Benedetti

doi:10.1016/j.critrevonc.2018.05.011

Cited by 45 publications

(34 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the continuous elucidation of the pathogenesis of endometrial cancer, more and more evidence shows that a large number of immune cells and cytokines can be seen in endometrial cancer tissue, and can stimulate endogenous anti-tumor immune response. Compared with other gynecological malignant tumors, endometrial cancer is most likely to benefit from immunotherapy [ 9 – 11 ]. The rationale for cancer immunotherapy can be summarized as reversing the tumors immuno-suppressive effects of the tumors or enhancing the inherent anti-tumor immune responses of the host [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Cao

Fischer

et al. 2021

Biomark Res

View full text Add to dashboard Cite

Tumor immunotherapy has attracted more and more attention nowadays, and multiple clinical trials have confirmed its effect in a variety of solid tumors. Immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell transfer (ACT), and lymphocyte-promoting cytokines are the main immunotherapy methods. Endometrial cancer (EC) is one of the most frequent tumors in women and the prognosis of recurrent or metastatic EC is poor. Since molecular classification has been applied to EC, immunotherapy for different EC subtypes (especially POLE and MSI-H) has gradually attracted attention. In this review, we focus on the expression and molecular basis of the main biomarkers in the immunotherapy of EC firstly, as well as their clinical application significance and limitations. Blocking tumor immune checkpoints is one of the most effective strategies for cancer treatment in recent years, and has now become the focus in the field of tumor research and treatment. We summarized clinical date of planned and ongoing clinical trials and introduced other common immunotherapy methods in EC, such as cancer vaccine and ACT. Hormone aberrations, metabolic syndrome (MetS) and p53 mutant and that affect the immunotherapy of endometrial cancer will also be discussed in this review.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Cao

Fischer

et al. 2021

Biomark Res

View full text Add to dashboard Cite

show abstract

“…Although specific therapeutic vaccines for tumor antigens (NY-ESO-1 or HER2) and therapeutic vaccines against viral antigens of HPV 16 and 18 have shown great efficacy, these studies do not include infections by other types of HPV [91].…”

Section: Immunotherapy In Premalignant Cervical Lesionsmentioning

confidence: 99%

Immune response in cervical intraepithelial neoplasms

2021

EJGO

View full text Add to dashboard Cite

The current study aims perform a comprehensive overview of the topic immune response in cervical intraepithelial neoplasms, summarizing the findings of literature. Data sources: PubMed database. Methods of study selection: A search for the following descriptors was performed in the PubMed database: descriptor ''immune response in cervical cancer and Human Papilloma Virus (HPV)''; ''immunotherapy in premalignant cervical lesions'' . Tabulation, integration and results: The articles identified were published between 1967 and 2021. We selected 85 articles for review on the subject (reference 16 onwards). This literature review shows the important role that the immune system plays in the development and progression of cervical cancer. Immune response in pre-neoplastic cervical lesions includes host defense mechanisms against the HPV, adaptive immunity and the function of cytokines. Predictive factors of viral persistence and progression of premalignant lesions may also be associated with immune response. Conclusion: One of the determining factors for the persistence or elimination of HPV infections and their evolution to pre-neoplastic lesions is the cellular immune response, as the progression or regression of the tumor depends on the type and amount of cytokines secreted by the body. The investigation of these immune reactions may provide new therapeutic targets for cervical intraepithelial neoplasms.

show abstract

“…The blockade of these immune checkpoints has translated into effective strategies for cancer immunotherapy. Immune checkpoints have achieved great success in suppressing lung cancer, breast cancer and melanoma [14][15][16][17]. Tumor mutation burden (TMB) is referred to the number of mutations that exist within a megabase of genomic territory [18].…”

Section: Introductionmentioning

confidence: 99%

Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma

Chen

Hao³

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of most common cancer with gradually increasing incidence and high mortality. chromogenic RCC (chRCC) is the third most common histological subtype of RCC, accounting for about 5-7% of RCC. In our study, the transcriptome expression profile data (n=89) of chRCC, corresponding clinical data (n=113) and the somatic mutation data (n=66) was obtained from the TCGA database. We first analyzed the mutation data of chRCC patients and divided chRCC patients into high and low tumor mutation burden (TMB) groups based on the median TMB. We found that high TMB was significantly associated with worse prognosis and could promote tumor metastasis and development. Moreover, four different immune-related genes (BIRC5, PDGFRL, INHBE, IL20RB) were also identified. We found that BIRC5 was significantly overexpressed in the high TMB group and correlated with worse prognosis. The result of univariate and multivariate COX analysis demonstrated that BIRC5 (HR=2.094) may serve as a prognostic indicator for patients with chRCC with high TMB. In addition, we identified the possible functional pathways of BIRC5 through GSEA enrichment. A positive correlation was obtained between BIRC5 and the abundance of CD4 + T cells. The result of our study revealed their correlation between the immune-related genes and clinicopathologic features as well as potential functional pathways as well as immune infiltrating cells, which may provide more data about the development of chRCC immunotherapy.

show abstract

Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers

Cited by 45 publications

References 97 publications

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Immune response in cervical intraepithelial neoplasms

Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma

Contact Info

Product

Resources

About